A MetAP2 inhibitor blocks adipogenesis, yet improves glucose uptake in cells

References

• Kopelman PG. Obesity as a medical problem. Nature. 2000;404(6778):635–643.
   PubMed Web of Science ®Google Scholar
• Friedman JM. Obesity in the new millennium. Nature. 2000;404(6778):632–634.
   PubMed Web of Science ®Google Scholar
• Roth J, Qiang X, Marban SL, et al. The obesity pandemic: where have we been and where are we going? Obes Res. 2004;12(Suppl 2):88S–101S.
   PubMedGoogle Scholar
• Bray GA, Tartaglia LA. Medicinal strategies in the treatment of obesity. Nature. 2000;404(6778):672–677.
   PubMed Web of Science ®Google Scholar
• Bouloumie A, Lolmede K, Sengenes C, et al. Angiogenesis in adipose tissue. Ann Endocrinol (Paris). 2002;63(2 Pt 1)):91–95.
   PubMed Web of Science ®Google Scholar
• Crandall DL, Hausman GJ, Kral JG. A review of the microcirculation of adipose tissue: anatomic, metabolic, and angiogenic perspectives. Microcirculation. 1997;4(2):211–232.
   PubMed Web of Science ®Google Scholar
• Silverman KJ, Lund DP, Zetter BR, et al. Angiogenic activity of adipose tissue. Biochem Biophys Res Commun. 1988;153(1):347–352.
   PubMed Web of Science ®Google Scholar
• Soares R Angiogenesis in diabetes. Unraveling the angiogenic paradox. The Open Circ Vascular J 2010; 3: 3–9.
   Google Scholar
• Costa R, Rodrigues I, Guardao L, et al. Modulation of VEGF signaling in a mouse model of diabetes by xanthohumol and 8-prenylnaringenin: unveiling the angiogenic paradox and metabolism interplay. Mol Nutr Food Res. 2017;61(4).
   PubMed Web of Science ®Google Scholar
• Soares R. Angiogenesis in the metabolic syndrome. In: Soares R, Costa C, editors. Oxidative stress, inflammation and angiogenesis in the metabolic syndrome. Dordrecht (Netherlands): Springer Sci Business Media; 2009. p. 85–99.
   Google Scholar
• Ingber D, Fujita T, Kishimoto S, et al. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature. 1990;348(6301):555.
   PubMed Web of Science ®Google Scholar
• Griffith EC, Su Z, Turk BE, et al. Methionine aminopeptidase (type 2) is the common target for angiogenesis inhibitors AGM-1470 and ovalicin. Chem Biol. 1997;4(6):461–471.
   PubMed Web of Science ®Google Scholar
• Selvakumar P, Lakshmikuttyamma A, Dimmock JR, et al. Methionine aminopeptidase 2 and cancer. Biochim Biophys Acta (BBA)- Rev Cancer. 2006;1765(2):148–154.
   PubMed Web of Science ®Google Scholar
• Brakenhielm E, Cao R, Gao B, et al. Angiogenesis inhibitor, TNP-470, prevents diet-induced and genetic obesity in mice. Circ Res. 2004;94(12):1579–1588.
   PubMed Web of Science ®Google Scholar
• Neels JG, Thinnes T, Loskutoff DJ. Angiogenesis in an in vivo model of adipose tissue development. Faseb J. 2004;18(9):983–985.
   PubMedGoogle Scholar
• Rupnick MA, Panigrahy D, Zhang CY, et al. Adipose tissue mass can be regulated through the vasculature. Proc Natl Acad Sci U S A. 2002;99(16):10730–10735.
   PubMed Web of Science ®Google Scholar
• Hughes TE, Kim DD, Marjason J, et al. Ascending dose-controlled trial of beloranib, a novel obesity treatment for safety, tolerability, and weight loss in obese women. Obesity (Silver Spring). 2013;21(9):1782–1788.
   PubMed Web of Science ®Google Scholar
• Kim DD, Krishnarajah J, Lillioja S, et al. Efficacy and safety of beloranib for weight loss in obese adults: a randomized controlled trial. Diabetes Obes Metab. 2015;17(6):566–572.
   PubMed Web of Science ®Google Scholar
• McCandless SE, Yanovski JA, Miller J, et al. Effects of MetAP2 inhibition on hyperphagia and body weight in Prader-Willi syndrome: A randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2017;19(12):1751–1761.
   PubMed Web of Science ®Google Scholar
• Shoemaker A, Proietto J, Abuzzahab MJ, et al. A randomized, placebo-controlled trial of beloranib for the treatment of hypothalamic injury-associated obesity. Diabetes Obes Metab. 2017;19(8):1165–1170.
   PubMed Web of Science ®Google Scholar
• Proietto J, Malloy J, Zhuang D, et al. Efficacy and safety of methionine aminopeptidase 2 inhibition in type 2 diabetes: a randomised, placebo-controlled clinical trial. Diabetologia. 2018.
   PubMed Web of Science ®Google Scholar
• Liu S, Widom J, Kemp CW, et al. Structure of human methionine aminopeptidase-2 complexed with fumagillin. Science. 1998;282(5392):1324–1327.
   PubMed Web of Science ®Google Scholar
• Sin N, Meng L, Wang MQ, et al. The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2. Proc Natl Acad Sci U S A. 1997;94(12):6099–6103.
   PubMed Web of Science ®Google Scholar
• Ramirez-Zacarias JL, Castro-Munozledo F, Kuri-Harcuch W. Quantitation of adipose conversion and triglycerides by staining intracytoplasmic lipids with Oil red O. Histochemistry. 1992;97(6):493–497.
   PubMedGoogle Scholar
• Das BC, Thapa P, Karki R, et al. Boron chemicals in diagnosis and therapeutics. Future Med Chem. 2013;5(6):653–676.
   PubMed Web of Science ®Google Scholar
• Dhurandhar EJ, Dubuisson O, Mashtalir N, et al. E4orf1: a novel ligand that improves glucose disposal in cell culture. PLoS One. 2011;6(8):e23394.
   PubMed Web of Science ®Google Scholar
• Na HN, Hegde V, Dubuisson O, et al. E4orf1 enhances glucose uptake independent of proximal insulin signaling. PLoS One. 2016;11(8):e0161275.
   PubMed Web of Science ®Google Scholar
• Cao Y. Angiogenesis modulates adipogenesis and obesity. J Clin Invest. 2007;117(9):2362–2368.
   PubMed Web of Science ®Google Scholar
• Lijnen HR. Angiogenesis and obesity. Cardiovasc Res. 2008;78(2):286–293.
   PubMed Web of Science ®Google Scholar
• Kim YM, An JJ, Jin YJ, et al. Assessment of the anti-obesity effects of the TNP-470 analog, CKD-732. J Mol Endocrinol. 2007;38(4):455–465.
   PubMed Web of Science ®Google Scholar
• Joharapurkar AA, Dhanesha NA, Jain MR. Inhibition of the methionine aminopeptidase 2 enzyme for the treatment of obesity. Diabetes Metab Syndr Obes. 2014;7:73.
   PubMedGoogle Scholar
• Scroyen I, Christiaens V, Lijnen H. Effect of fumagillin on adipocyte differentiation and adipogenesis. Biochim Biophys Acta. 2010;1800(4):425–429.
   PubMed Web of Science ®Google Scholar
• Lijnen HR, Frederix L, Van Hoef B. Fumagillin reduces adipose tissue formation in murine models of nutritionally induced obesity. Obesity (Silver Spring). 2010;18(12):2241–2246.
   PubMed Web of Science ®Google Scholar
• White HM, Acton AJ, Considine RV. The angiogenic inhibitor TNP-470 decreases caloric intake and weight gain in high-fat fed mice. Obesity (Silver Spring). 2012;20(10):2003–2009.
   PubMed Web of Science ®Google Scholar
• Tansey JT, Sztalryd C, Hlavin EM, et al. The central role of perilipin a in lipid metabolism and adipocyte lipolysis. IUBMB Life. 2004;56(7):379–385.
   PubMed Web of Science ®Google Scholar
• Darlington GJ, Ross SE, MacDougald OA. The role of C/EBP genes in adipocyte differentiation. J Biol Chem. 1998;273(46):30057–30060.
   PubMed Web of Science ®Google Scholar
• Rosen ED. The transcriptional basis of adipocyte development. Prostaglandins, Leukotrienes Essent Fatty Acids. 2005;73(1):31–34.
   PubMed Web of Science ®Google Scholar
• Wu Z, Xie Y, Morrison RF, et al. PPARgamma induces the insulin-dependent glucose transporter GLUT4 in the absence of C/EBPalpha during the conversion of 3T3 fibroblasts into adipocytes. J Clin Invest. 1998;101(1):22–32.
   PubMed Web of Science ®Google Scholar
• Wang H, Scott R. Inhibition of distinct steps in the adipocyte differentiation pathway in 3T3 T mesenchymal stem cells by dimethyl sulphoxide (DMSO). Cell Prolif. 1993;26(1):55–66.
   PubMed Web of Science ®Google Scholar
• Vogel C, Marcotte EM. Insights into the regulation of protein abundance from proteomic and transcriptomic analyses. Nat Rev Genet. 2012;13(4):227–232.
   PubMed Web of Science ®Google Scholar
• Burkey BF, Hoglen NC, Inskeep P, et al. Preclinical efficacy and safety of the novel antidiabetic, antiobesity MetAP2 inhibitor ZGN-1061. J Pharmacol Exp Ther. 2018;365(2):301–313.
   PubMed Web of Science ®Google Scholar